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Abstract
Background: Combination treatments, preferably containing an artemisinin derivative, are recommended to
improve efficacy and prevent Plasmodium falciparum drug resistance. Artemether-lumefantrine (AL) and artesunate-
amodiaquine (AA) are efficacious regimens that have been widely adopted in sub-Saharan Africa. However, most
study designs ignore the effects of these regimens on peripheral parasitaemia in the first 24 hours of therapy. The
study protocol was designed to evaluate more closely the early effects and the standard measures of efficacies of
these two regimens.
Methods: In an open label, randomized controlled clinical trial, children aged 12 months to 132 months were
randomized to receive AL (5-14 kg, one tablet; 15-24 kg, two tablets and 25-34 kg, three tablets twice daily) or
artesunate (4 mg/kg daily) plus amodiaquine (10 mg/kg daily) for three days. Peripheral blood smears were made
hourly in the first 4 hours, 8 h, 16 h, 24 h, and daily on days 2-7, and on days 7, 14, 21, 28, 35, and 42 for
microscopic identification and quantification of Plasmodium falciparum.
Results: A total of 193 children were randomized to receive either AL (97) or AA (96). In children that received
both medications, early response of peripheral parasitaemia showed that 42% of children who received AL and
36.7% of those who received AA had an immediate rise in peripheral parasitaemia (0-4 h after treatment) followed
by a rapid fall. The rise in parasitaemia was significant and seems to suggest a mobilization of asexual parasites
from the deep tissues to the periphery. Days 3, 7, 14, 28, and 42 cure rates in the per protocol (PP) population
were >90% in both groups of children. Both drug combinations were well tolerated with minimal side effects.
Conclusion: The study showed the high efficacy of AL and AA in Nigerian children. In addition the study
demonstrated the mobilisation of asexual parasites from the deep to the periphery in the early hours of
commencing ACT treatment in a subset of patients in both study groups. It is unclear whether the early parasite
dynamics discovered in this study play any role in the development of drug resistance and thus it is important to
further evaluate this discovery. It may be useful for studies investigating delay in parasite clearance of artemisinin
derivatives as a way of monitoring the development of resistance to artemisinin to assess the early effects of the
drugs on the parasites.
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The World Health Organization (WHO) recommends
artemisinin-based combination therapy (ACT) for the
treatment of malaria in countries experiencing resistance
to anti-malarial drug monotherapy [1]. Artemisinin deri-
vatives are noted for rapid reduction of parasite biomass
[2]. This class of drug have very short half-lives and
their use alone in monotherapy is associated with a high
percentage of treatment failure. Artemisinins are con-
ventionally used in combination with slower acting anti-
malarial drugs. The rationale for combination therapy is
to improve the cure rate of infections responding inade-
quately to mono-therapy and possibly to prevent or
d e l a yt h ee m e r g e n c eo fr e s i s t a n c et oo t h e rd r u g s[ 1 ] .
Studies have confirmed that the advantages of combin-
ing artemisinins with partner drugs far exceed the disad-
vantages [3]. This has led to their widespread use as first
line therapies worldwide.
T h eg u i d e l i n e sf o rt h ec o m p a r a t i v es t u d i e so fa n t i -
malarial therapies have largely remained unchanged
since the time of widespread use of chloroquine and
other monotherapies. The standard endpoints of efficacy
studies remain the evaluation of events around the fol-
lowing days of therapy; days 3, 7, 14, 28, and more
recently day 42. Most studies on ACT using these stan-
dard endpoints have consistently reported similarities in
efficacies of ACT with cure rates above 90% [4-10]. This
is not surprising considering the fact that the artemisi-
nins, the fastest anti-malarials, are components of both
arms of comparative studies. In addition, the drugs kill
parasites more rapidly than conventional anti-malarials,
and are active against both the sexual and asexual stages
of the parasite cycle. Artemisinin fever clearance time is
shortened to 32 hours as compared with 2-3 days with
older agents [11]. Using current protocols of evaluation
of efficacy, subtle differences between different forms of
ACT may be masked on account of the rapidity of anti-
malarial effects of the Artemisinin component. In
addition these masked differences may be involved in
eventual reduction of susceptibility of parasites to ACT,
as already being reported by some studies [12-14]. The
need to evaluate the precise estimate of the risk of treat-
ment failure with ACT using several methods of analysis
has been attempted by some authors [15,16]. It has
become important that more sensitive and robust meth-
ods of assessing the in vivo efficacies of ACT be evolved
in view of the presence of artemisinins in both arms of
studies evaluating ACT.
In this study, the comparative efficacy and safety of
two different forms of ACT [artesunate-amodiaquine
(AA) and artemether-lumefanthrine (AL)] was evaluated
using a modified protocol to evaluate two time points of
efficacy; early effects (≤ 72 hours of therapy) and late
effects (>72 h to 42
nd day of therapy). The early and late
efficacy of these two different forms of ACT on periph-
eral asexual falciparum parasitaemia was assessed.
Methods
Study site, design and patients
The study was a parallel, open label, randomized con-
trolled clinical trial conducted at the malaria clinic of
the University College Hospital, Ibadan, Nigeria. Ibadan
is located in the rain forest belt in south-western
Nigeria. Malaria transmission is intense and occurs all
year round in the study area. Children aged 12 months
to 132 months were enrolled in the study in accordance
with the following inclusion criteria: signs and symp-
toms compatible with acute uncomplicated malaria, axil-
lary temperature >37.4°C, microscopically confirmed
asexual forms of P. falciparum with parasite density of
>2,000 parasite/μL, willingness to comply with protocol,
and parental guardian written informed consent. Chil-
dren with severe malnutrition, presence of mixed infec-
tion, signs of severe and complicated malaria or other
febrile illnesses and history of hypersensitivity to any of
the study drugs were excluded from the study.
Ethical issues
The study was conducted in accordance to Good Clini-
cal Practice and the Helsinki declaration. Ethical clear-
ance was obtained from the University of Ibadan/
University College Hospital Joint Institutional Review
Committee. A written or witnessed verbal informed
consent was obtained from the parent or guardian of
each child before any study-related procedure was car-
ried out.
Treatment allocation and case management
At enrolment, children who satisfied the enrolment cri-
teria were examined thoroughly and weighed. Thick and
thin blood films were prepared from a finger prick
under aseptic conditions and blood spots collected on
filter paper for molecular analysis at enrolment.
Enrolled children were allocated to one of two treat-
ment groups according to a pre-generated randomiza-
tion table. Randomization was done using a computer
generated random sequence. These sequences were con-
cealed in envelopes prior to commencement of the
study. However, the study was not blinded. The study
physician opened the drug envelopes only after the chil-
dren were allocated according to the computer gener-
ated drug sequence. Children randomized to group 1
received AL twice daily for three days. AL was given
according to the weight of enrolled children. Children
weighing 5 to <15 kg received one tablet, those weighing
15 to <25 kg received two tablets while those weighing
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days. Each tablet of AL contained 20 mg artemether and
120 mg lumefantrine. Patients randomized to group 2
received AA. Artesunate was administered at a dose of 4
mg/kg body weight once daily for three days and amo-
diaquine at a dose of 10 mg amodiaquine base/kg body
weight once daily for three days. The tablet formulations
of both drugs were crushed and dissolved in milk (AL)
or water (AA) before administration. Study drugs were
administered supervised by a nurse or a physician. The
enrolled patients were admitted to hospital ward for
three days for observation of drug administration and
clinical states. After administration of drugs, patients
were observed for 30 min and the dose was re-adminis-
tered if the patient vomited within the period. Febrile
children with axillary temperature ≥38°C were exposed,
tepid-sponged and given oral paracetamol. Children
were withdrawn for the following reasons: withdrawal of
consent, protocol violation, repeated vomiting or loss to
follow-up.
Patient follow-up
Study participants were followed up daily on days 0-7
and on days 14, 21, 28, 35 and 42. At each visit children
were physically examined and their vital signs recorded.
In addition, thick blood films were prepared from finger
prick blood samples. Thick blood films were prepared
hourly for the first 4 hours, at 8, 16 and 24 hours (day
0) following therapy. Subsequently thick films were
made daily on days 1-7, 14, 21, 28, 35 and 42. These
were stained with 10% fresh Giemsa stain and examined
for the presence of asexual forms of P. falciparum
under a light microscope at 1,000× magnification. Blood
spots were also collected on filter paper for molecular
analysis at entry and daily for the first 7 days, on days
14, 21, 28, 35 and 42.
Children who were not brought to the clinic on
scheduled days were visited at home for the follow-up
procedures. Each child and the parent or guardian was
questioned about symptoms observed following com-
mencement of therapy. Children who failed treatment
were re-treated with artesunate-mefloquine.
Evaluation of efficacy
Efficacy was comparatively evaluated using two time
points. Early drug effects were classified as effects occur-
ring between 0 h and < 72 h of treatment. Late effects
were those occurring between > 72 h and day 42 post-
treatment.
Early treatment failure (ETF), defined as development
of danger signs of malaria or severe malaria on post-
treatment days 1, 2 or 3, in the presence of parasitaemia,
parasitaemia on day 2 higher than day 0 count irrespec-
tive of axillary temperature, parasitaemia on day 3
which is >25% of count on day 0 and parasitaemia on
day 3 with axillary temperature 37.5°C [17].
Late clinical failure (LCF) was defined as development
of danger signs or severe malaria after day 3 in the pre-
sence of parasitaemia without previously meeting any of
the criteria of ETF and presence of parasitaemia and axil-
lary temperature of 37.5°C on any day from day 4 to day
42, without previously meeting any of the criteria of ETF.
Late parasitological failure (LPF) was defined as pre-
sence of parasitaemia on any day from day 7 to day 42
and axillary temperature of < 37.5°C without previously
meeting any of the criteria of ETF or LCF.
Adequate clinical and parasitological response (ACPR)
was defined as absence of parasitaemia on day 42 irre-
spective of axillary temperature without previously
meeting any of the ETF, LCF or LPF.
Discrimination between recrudescence and re-infec-
tions in treatment failures was done using molecular ana-
lysis [18,19]. Isolates from each P. falciparum infection in
the study were characterized on the basis of the fragment
size of alleles of msp-2 after amplification by PCR.
A recrudescent infection was defined as the occurrence
of the same or a subset of the alleles at each of the
families (FC27 or IC1/3D7) of msp-2 in the primary and
post-treatment samples. A lack of allelic identity in the
two families of msp-2 in matched primary and post-treat-
ment samples indicated a newly acquired infection. Infec-
tions were defined as polyclonal if parasites in matched
primary and post-treatment samples from the same
patient showed more than one allele of FC27 or IC1/3D7
families of msp-2. If an isolate had one allele at each of
the families, the clone number was taken to be one.
Assessment of drug related adverse events
An adverse event (AE) was defined as signs, symptoms
or abnormal laboratory finding not present at enrol-
ment, but occurring during follow-up, or being present
at day 0 and becoming worse during follow-up despite
clearance of parasitaemia. All AEs were monitored and
recorded. Assessment was by asking about the progress
of presenting symptoms and new symptoms noticed
during follow-up, physical examination, and or labora-
tory evaluation.
Data analysis
Data collected were recorded in case record forms and
entered into Epi-info version 6.04 database for analysis.
SPSS version 16 was also used for analysis. Efficacy ana-
lysis of the data was done for the intention to treat
(ITT) and per protocol (PP) populations. All children
enrolled into the study were considered ITT. Patient
who completed the study without violating the study
protocol were considered as PP population. Parasite
densities are reported as geometric mean parasite
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normally distributed dataw e r ec o m p a r e du s i n gS t u -
dent’s t-test and analysis of variance (ANOVA). Propor-
tions were compared by chi-square. Numerical values
are given as means ± SD, p-values < 0.05 was taken as
statistically significant.
Results
A total of 1,888 children were screened for the study and
193 consented after meeting the inclusion criteria. Ninety-
seven (97) children were randomized to receive AL and 96
were randomized to receive AA. Ten (10) of the children
enrolled (5.2%) were lost to follow-up: four patients from
AL group and six (6) from AA group (Figure 1).
T h eb a s e l i n ec h a r a c t e r i s t i cs of study participants in
the two groups were similar. The three most common
presenting complaints were fever (100%), vomiting
(51%) and abdominal pain (35%). Ninety-three of 97
(95.9%) patients treated with AL completed the study
while 90/96 (93.7%) of those that receive AA completed
the study (per protocol population) (Table 1).
Early Efficacy evaluation
Responses to therapy were good and prompt in all study
participants. Mean fever clearance times (FCT) for AL
and AA were 29.9 ± 18.4 vs. 28.9 ± 12.7 hours, respec-
tively (p = 0.630). The 24 and 48-h parasite reduction
ratios (PRR) were 11 × 10
3,7 8×1 0
3,a n d1 4×1 0
3,6 9
×1 0
3 for AL and AA (p = 0.562, 0.534), respectively,
while mean parasite clearance times (PCT) were 28.6 ±
18.4 hours AL and 24.0 ± 15.4 hours for AL and AA
respectively (p = 0.067). Cure rates by day 3 in both
groups were 100% (Table 2). The overall patterns of
parasite reduction in children in the two groups were
similar.
Figure 1 Trial Profile of Nigerian children enrolled in a AA and
AL efficacy study conducted at the Malaria Clinic, Malaria
Research Laboratories, College of Medicine, University of
Ibadan, Nigeria.
Table 1 Pre-enrolment characteristics of 183 children
involved in the study (per protocol population).
Variable AL
(N = 93)
AA
(N = 90)
Male:female 45:48 43:47
Age (yr) 6.3 ± 2.5 6.8 ± 2.6
95% CI 5.95 − 7.38 5.89 − 7.38
Duration of illness (d) 2.7 ± 1.5 2.5 ± 1.1
95% CI 2.32 − 2.16 2.21 − 2.87
Weight (kg) 18.2 ± 5.3 18.9 ± 4.6
95% CI 17.52 − 20.52 17.7 − 20.26
Temperature°C 38.4 ± 1.2 38.2 ± 1.2
95% CI 38.05 − 38.77 37.96 − 38.64
Hematocrit (%) 32.6 ± 3.4 32.5 ± 3.9
95% CI 31.88 − 33.80 31.28 − 33.60
GMPD (/μl of blood) 78195 69288
Range 2837 − 1105263 2791 − 1125000
AL = artemether-lumefanthrine; AA = artesunate-amodiaquine
GMPD = geometric mean parasite density; SD = standard deviation
d = days; *values are given as mean ± SD.
Table 2 Therapeutic responses of the enrolled children
after treatment with AL or AA.
Treatment groups
AL AA p-value
P↑ % 42 36.7 0.563
PRR 24 h 11 × 10
3 14 × 10
3 0.279
FCT (hours) 29.9 ± 18.4 28.9 ± 12.7 0.630
95% CI 26.83 - 32.82 25.81 - 31.93
PCT (hours) 28.6 ± 18.4 24.0 ± 15.4 0.067
95% CI 25.23 - 33.79 20.71 - 28.13
ETF 0 0 1.000
LPF 7.5% 7.8% 0.830
ACPR 92.5% 92.2% 0.830
PCR-corrected cure rates 93.5% 93.3% 0.955
P↑ proportion with increase in peripheral blood parasitaemia in the first few
hours of therapy
PRR = parasite reduction ratio at 24 hours; FCT = fever clearance time;
PCT = parasite clearance time; ETF = early treatment failure; LPF = late
treatment failure
ACPR = adequate clinical and parasitological response; Values are reported as
mean ± SD or as proportions
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Analysis of drug effects on hourly changes in peripheral
asexual parasitaemia in the first 24 hours following treat-
ment showed that there were two sub-groups; those in
whom parasitaemia increased in the first 4 hours after
the first dose of the medications and those that did not
show any increase in peripheral parasitaemia (Figure 2).
Pre-enrolment characteristics of these two sub-groups
were similar (Table 3). Forty-two percent (42%) of the
patients who received AL had an initial elevation of per-
ipheral parasitaemia, while the remaining did not. In
those that received AA 36.7% showed an initial increase
in peripheral parasitaemia. This proportion of children
that showed initial increase in parasitaemia in the two
study groups was similar (42% vs. 36.7%, p-value 0.377).
Parasitaemia in patients that showed increase in periph-
eral asexual parasitaemia peaked at one hour after the
first dose of AL or AA. Peripheral asexual parasitaemia in
children who did not show initial increase and those that
showed increase were the same at all time points except
at 4 and 8 hours. Geometric means of parasitaemia at 4
and 8 hours after first dose of the study drugs were
10579 parasites/μL vs 55,809 parasites/μL (p = 0.011)
and 2,297 parasites/μL vs. 15,409 parasites/μL (p = 0.002)
for sub-groups that showed no increase and increase
respectively.
In the AL and AA groups, peripheral asexual parasite
changes in the first 24 hours and at others time points
of the study were similar between the two sub-groups
described above. Geometric means of parasitaemia at
0 hour and 1 hour in the two subgroups of AL and AA
in those that showed no increase in parasitaemia in the
first hour following therapy were 99,028 parasites/μL
and 50,075 parasites/μL (for AL), and 72,927 parasites/
μL and 33,167 parasites/μL( f o rA A )r e s p e c t i v e l y
(p-values 0.133 and 0.302). Geometric means of parasi-
taemia at 0 hour and 1 hour in the two subgroups of
AL and AA in those that showed increase in parasitae-
mia in the first hour following therapy were 53,001
parasites/μL and 60,744 parasites/μL( f o rA L )a n d
63,424 parasites/μL and 106,185 parasites/μL( f o rA A )
[p-values 0.698 and 0.248]. PRR in the first 24 hours
and 48 hours were similar in both groups (Figure 3).
Late efficacy evaluation
Intention to treat (ITT) population: Day 14, 28, and 42
cure rates for AL and AA were 100%, 97.9%, 92.8%, and
100%, 96.9%, 93.8% respectively. PCR corrected cure
rates on day 28, 42 for AL and AA were 97.9%, 94.8%,
and 97.9%, 93.8% respectively. Per-protocol (PP) popula-
tion: Day 14, 28, and 42 cure rates for AL and AA were
100%, 96.8%, 92.5%, and 100%, 97.8%, 92.2% respec-
tively. PCR corrected cure rates on day 28, 42 for AL
and AA were 97.8%, 93.5%, and 97.8%, 93.3% respec-
tively (Table 2). All rates were similar between the two
drug groups.
Safety evaluation
The study drugs were well tolerated. All recorded
adverse events were mild and transient. Mean resolution
time for all adverse drug events reported during the
study was 2.86 ± 1.8 days. Twelve children in the study
reported adverse drug events. These adverse drug events
were reported within the first week of treatment. Com-
mon adverse events reported were abdominal pain,
vomiting, weakness, and headache. A child who was
treated with AL developed a transient generalized papu-
lar rash with itching. No child had therapy discontinued
or modified on account of adverse drug event Table 4 is
a summary of adverse drug events reported by the chil-
dren during the study.
Discussion
Artemisinin based combination therapy (ACT) was
formally introduced in Nigeria in 2005 following the pro-
gressive decline in efficacy of chloroquine and sulphadox-
ine-pyrimethamine. The two most widely adopted ACT
regimens are AL and AA [20]. The results of this study
showed that both combination therapies were safe and
well tolerated. In addition, AA and AL rapidly eliminated
asexual parasites and they retain their high efficacy in
Nigerian children. Overall, the study showed a high effi-
cacy of the two forms of ACT in Nigerian children; cure
Figure 2 Mean peripheral parasitaemia in the first 24 h in
children with increased parasitaemia during the first hours of
treatment and in those who showed no increase in peripheral
asexual parasitaemia. AL1: children who did not have initial
increase in peripheral parasitaemia after treatment with artemether-
lumefanthrine AL2: children who had an increase in peripheral
parasitaemia in the first few hours after commencing treatment
with artemether-lumefanthrine AA1: children who did not have
initial increase in peripheral parasitaemia after treatment with
Artesunate-amodiaquine AA2: children who had an increase in
peripheral parasitaemia in the first few hours after commencing
treatment with Artesunate-amodiaquine.
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results are consistent with the high cure rates known to be
associated with ACT in other malaria endemic areas of
Africa [21-23], although other reports suggest a marginally
higher day 28 PCR-corrected cure rate for AL over AA
[24]. Generally, studies from East Africa seem to suggest
that AL has more clinical benefits than AA, while studies
from West Africa show that AA tend to have a marginally
better efficacy over AL [25].
The effects of the study drugs on asexual parasites
immediately following treatment uncovered an unex-
pected finding. Two patterns of asexual parasite
responses occurred; children that experienced an acute
rise in peripheral parasitaemia hours after commencing
treatment and those that did not. This effect was
uncovered due to frequent blood sampling for malaria
parasite evaluation in the first 24 hours of the study.
Daily sampling, as recommended by the WHO, would
have missed this important finding because these effects
occurred within 24 hours of initiating treatment. Parasi-
taemia reached a peak at 1 hour in the sub-group of
children that had an initial rise in peripheral parasitae-
mia after commencing therapy. Analysis of demographic
and clinical parameters of children in these two sub-
groups (Table 3) did not point to any factor that may
explain this acute rise in parasitaemia after starting
treatment, although pre-treatment parasite density was
marginally lower in the sub-group of children that had
an initial acute rise in peripheral parasitaemia at com-
mencement of therapy compared to those that did not
(72,927 parasites/μL vs 99,028 parasites/μLp - v a l u e
0.133). This marginal difference may point to the fact
that children who had a rapid rise in asexual parasitae-
mia after commencing treatment might have had a
Table 3 Baseline parameters (at enrolment) between the two sub-groups of patients that showed different peripheral
asexual parasitaemia in the immediate hours following administration of the first dose of treatment medications
(all patient analysis, intention to treat population)
Parameters Sub-group with no increase in
peripheral asexual parasitaemia following
onset of therapy
Sub-group with initial increase in
peripheral asexual parasitaemia following
onset of therapy
Number (%)
N = 193
118 (60.9%) 75 (39.1%)
Sex ratio M:F 61:56 34:42
Mean age (years) ± SD 6.6 ± 2.5 6.6 ± 2.7
95% CI 4.71 − 7.72 5.01 − 8.72
Mean weight (kg) ± SD 18.6 ± 5.1 18.7 ± 5.0
95% CI 15.98 − 23.30 14.99 − 20.28
Mean duration of fever (days) ± SD 2.7 ± 1.5 2.7 ± 1.1
95% CI 1.98 − 3.87 1.74 − 3.89
Mean temperature (°C) ± SD 38.3 ± 1.2 38.3 ± 1.2
95% CI 37.78 − 39.13 38.18 − 39.74
Mean hematocrit (%) ± SD 33.1 ± 3.6 32.1 ± 3.7
95% CI 29.90-33.53 28.89 − 33.29
Geometric Mean of 0 hour parasitaemia 82870 60437
Range 2837 − 1105263 2657 − 1125000
CI = Confidence Interval
Figure 3 Proportion of children with peripheral asexual
parasitaemia plotted against time (hours).
Table 4 Adverse drug events reported within the first
week of the study.
AL AA
No. of children 4 (4.4%) 8 (8.3%)
Abdominal pain 2 (2.2%) 3 (3.1%)
Vomiting 0 (0%) 2 (2.1%)
Weakness 0 (0%) 2 (2.1%)
Headache 1 (1.1%) 1 (1.0%)
Skin rash with itching 1 (1.1%) 0 (0%)
AL artemether-lumefanthrine; AA artesunate-amodiaquine
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This acute mobilization of asexual parasites from the
deep tissues to the periphery may be attributable to the
action of ACT in enhancing the clearance of the para-
sites from the blood by exposing the parasites to the
drug and driving them to the spleen where they are
cleared from the blood (Happi and Sowunmi, personal
communication). In addition, the mobilization of para-
sites from the deep tissues by ACT may be responsible
for reduction in the incidence of development of severe
and complicated malaria attributed to ACT [26]. Other
explanations may be that a proportion of native Pf a l c i -
parum in the Nigerian population has a higher tendency
to sequestration, or that a proportion of the children
have a tendency to having more of sequestered parasites.
These postulates remain to be fully explored.
Studies in the past have described increase in parasitae-
mia 6 to 12 hours after administration of parenteral anti-
malarial drugs and have attributed this phenomenon of
natural progression of sequestered parasites on account
of a lag period between drug administration, absorption
and onset of parasitocidal effects of the drugs [27]. The
lag period allows the natural multiplication of parasites
to continue until the drugs start acting. Silachamroon
et al [28], in a retrospective study in 2001, reported that
early rising parasitaemia after treatment with artemisinin
derivatives was very common despite their ability to clear
parasites from the blood. These authors stated that 25.8%
of the patients with uncomplicated malaria and 41.3% of
those that had complicated malaria encountered early
rise in parasitaemia.
The clinical efficacy of artemisinin is known to be
characterized by an almost immediate onset and rapid
reduction of parasitaemia [29]. However, this study
showed that before the rapid decline in parasitaemia on
account of drug action, there is a brief interval of rapid
rise in parasitaemia within the first four hours of start-
ing ACT treatment in a subgroup of children followed
by a rapid clearance within 24 hours. Although the rea-
sons behind the initial rise in parasitaemia in some
patients as shown in this study remain unclear, Sila-
chamroon and colleagues [28] have reported previously
that early rising parasitaemia in falciparum malaria trea-
ted with artemisinin derivatives is not associated with
eventual treatment outcome.
Based on the observations of potential mobilization of
parasites from the tissues to the periphery in this study,
it is possible that AA and AL may have a property of
rapidly releasing parasites from sequestration sites in the
deep tissues. It is not clear if the early parasite dynamics
discovered in this study play any role in the develop-
ment of drug resistance and thus it is important to
further evaluate this finding. Studies investigating delay
in parasite clearance of artemisinin derivatives as a way
of monitoring the development of resistance to artemisi-
nin should also assesses the early effects of the drugs on
the parasites.
Conclusions
The two forms of ACT studied, AL and AA, had similar
efficacies and effects on peripheral asexual Plasmodium
falciparum parasitaemia in the treatment of acute
uncomplicated malaria in Nigerian children. Therapeutic
responses were rapid, and efficacy at day 42 was above
90% for both combinations. Both drugs were well toler-
ated with minimal side effects.
The study also revealed that asexual parasite dynamics
in the early hours of initiating therapy showed two pat-
terns; those who had an early rise in peripheral parasi-
taemia immediately after treatment and those who did
not. The significance of this finding remains to be
further explored and explained.
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